Indivior Pharmaceuticals, Inc.
INDVNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for INDV. That does not mean none is planned.
Get an email about INDV's next catalysts
Track Indivior Pharmaceuticals (INDV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
WebsiteRBP-7000
Schizophrenia
RBP-6000
Opioid Dependence
hydromorphone
Opioid Use Disorder
Suboxone
Moderate to Severe Opioid Use Disorder
Cocaine
Opioid Dependence
Buprenorphine/naloxone film strip
Opioid-related Disorders
buprenorphine and naloxone
Opioid Use Disorder
Subutex®/Suboxone®
Opioid Related Disorder
Sublocade
Moderate to Severe Opioid Use Disorder
Buprenorphine hydrochloride fast dissolving tablet (FDT)
Opioid Dependency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RBP-7000 | Phase 3 | Schizophrenia | - | - |
RBP-6000 | Phase 3 | Opioid Dependence | - | - |
hydromorphone | Phase 2 | Opioid Use Disorder | - | - |
Suboxone | Phase 2 | Moderate to Severe Opioid Use Disorder | - | - |
Cocaine | Phase 2 | Opioid Dependence | - | - |
Buprenorphine/naloxone film strip | Phase 2 | Opioid-related Disorders | - | - |
buprenorphine and naloxone | Phase 2 | Opioid Use Disorder | - | - |
Subutex®/Suboxone® | Phase 2 | Opioid Related Disorder | - | - |
Sublocade | Phase 2 | Moderate to Severe Opioid Use Disorder | - | - |
Buprenorphine hydrochloride fast dissolving tablet (FDT) | Phase 2 | Opioid Dependency | - | - |
Frequently asked questions
What is in Indivior Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Indivior Pharmaceuticals, Inc.'s (INDV) pipeline across Phase 3, Phase 2. Its lead program is RBP-6000 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Indivior Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Indivior Pharmaceuticals, Inc. (INDV) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INDV biotech catalysts?→
Add INDV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Indivior Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.